evinacumab
evinacumab: sourced relationships with 1 company · 2 clinical trials tracked.
evinacumab evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could evinacumab → RARE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) Homozygous Familial Hypercholesterolemia (HoFH) | Approved |
Clinical Trial Registry Records (2)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALN-ANG3 in Participants With Diabetic Kidney Disease
Primary endpoint: Percent Change in Urine Albumin to Creatinine Ratio (UACR)
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia in a Real Life Setting in Canada
Primary endpoint: Change in lipid profile
Frequently asked questions
Which companies have sourced relationships with evinacumab?
evinacumab has dated SEC/FDA relationship records for Ultragenyx Pharmaceutical Inc..
How many clinical trials involve evinacumab?
BioSniper tracks 2 clinical trials involving evinacumab.